Entering text into the input field will update the search result below

Verisante Technology Inc. (VRSEF) Begins Trading on the OTCQX

May 27, 2011 11:27 AM ETVRSEF
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Verisante Technology Inc. is a Canadian medical device company committed to commercializing innovative systems for the early detection of cancer. The company’s exclusive platform technology allows it to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers.

The company currently has two products on the market. The first product is the Verisante Aura which is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. The second product is the Verisante Core which uses the same basic technology for the early detection of other cancers including lung, colon and cervical.

Verisante Technology announced yesterday that its stock had begun trading on the OTC market’s highest tier for international stocks, OTCQX International. Investors can find current financial disclosure and real-time Level 2 quotes for the company on otcqx.com or otcmarkets.com. Verisante’s principal American liaison on OTCQX is Hodgson Russ LLP.

The move to the OTCQX will give the company more visibility and its shareholders superior information on Verisante. The reason behind the move for the company is to build investor confidence and its shareholder base in the United States.

For more information on Verisante Technology, please visit its website at verisante.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.